| Characteristics . | Values . |
|---|---|
| Age, years, mean (s.d.) | 60 (12) |
| Female, n (%) | 68 (80) |
| Currently smoking, n (%) | 10 (12) |
| Disease duration, months, median (IQR) | 72 (33, 132) |
| RP duration, months, median (IQR) | 132 (60, 240) |
| lcSSc, n (%) | 51 (60) |
| Digital ulcers (current), n (%) | 6 (7) |
| Pitting scars (current), n (%) | 36 (42) |
| SSc pattern on NC, n (%) | 66 (78) |
| Early SSc pattern, n | 10 |
| Active SSc pattern, n | 27 |
| Late SSc pattern, n | 29 |
| Vasoactive medication, n (%) | 57 (67) |
| Prior RCS scorea (1–10), mean (s.d.) | 6.4 (1.6) |
| Characteristics . | Values . |
|---|---|
| Age, years, mean (s.d.) | 60 (12) |
| Female, n (%) | 68 (80) |
| Currently smoking, n (%) | 10 (12) |
| Disease duration, months, median (IQR) | 72 (33, 132) |
| RP duration, months, median (IQR) | 132 (60, 240) |
| lcSSc, n (%) | 51 (60) |
| Digital ulcers (current), n (%) | 6 (7) |
| Pitting scars (current), n (%) | 36 (42) |
| SSc pattern on NC, n (%) | 66 (78) |
| Early SSc pattern, n | 10 |
| Active SSc pattern, n | 27 |
| Late SSc pattern, n | 29 |
| Vasoactive medication, n (%) | 57 (67) |
| Prior RCS scorea (1–10), mean (s.d.) | 6.4 (1.6) |
Vasoactive medication included the use of calcium channel blockers, endotheline-1 antagonists and PDE5 inhibitors.
Mean RCS during the 2 weeks before the start of the trial (without wearing gloves).
NC: nailfold capillaroscopy.
| Characteristics . | Values . |
|---|---|
| Age, years, mean (s.d.) | 60 (12) |
| Female, n (%) | 68 (80) |
| Currently smoking, n (%) | 10 (12) |
| Disease duration, months, median (IQR) | 72 (33, 132) |
| RP duration, months, median (IQR) | 132 (60, 240) |
| lcSSc, n (%) | 51 (60) |
| Digital ulcers (current), n (%) | 6 (7) |
| Pitting scars (current), n (%) | 36 (42) |
| SSc pattern on NC, n (%) | 66 (78) |
| Early SSc pattern, n | 10 |
| Active SSc pattern, n | 27 |
| Late SSc pattern, n | 29 |
| Vasoactive medication, n (%) | 57 (67) |
| Prior RCS scorea (1–10), mean (s.d.) | 6.4 (1.6) |
| Characteristics . | Values . |
|---|---|
| Age, years, mean (s.d.) | 60 (12) |
| Female, n (%) | 68 (80) |
| Currently smoking, n (%) | 10 (12) |
| Disease duration, months, median (IQR) | 72 (33, 132) |
| RP duration, months, median (IQR) | 132 (60, 240) |
| lcSSc, n (%) | 51 (60) |
| Digital ulcers (current), n (%) | 6 (7) |
| Pitting scars (current), n (%) | 36 (42) |
| SSc pattern on NC, n (%) | 66 (78) |
| Early SSc pattern, n | 10 |
| Active SSc pattern, n | 27 |
| Late SSc pattern, n | 29 |
| Vasoactive medication, n (%) | 57 (67) |
| Prior RCS scorea (1–10), mean (s.d.) | 6.4 (1.6) |
Vasoactive medication included the use of calcium channel blockers, endotheline-1 antagonists and PDE5 inhibitors.
Mean RCS during the 2 weeks before the start of the trial (without wearing gloves).
NC: nailfold capillaroscopy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
